Contribution of dysregulated serum magnesium to mortality in hemodialysis patients with secondary hyperparathyroidism: A 3-year cohort study

Clinical Kidney Journal

Volumn 8, Issue 6, 2015, Pages 744-752

  Kurita, Noriaki ^a,b,c   Akizawa, Tadao ^d   Fukagawa, Masafumi ^e   Onishi, Yoshihiro ^b   Kurokawa, Kiyoshi ^f   Fukuhara, Shunichi ^a,c  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b Institute for Health Outcomes and Process Evaluation Research   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f NATIONAL GRADUATE INSTITUTE FOR POLICY STUDIES   (Japan)

Author keywords

Cohort study; Magnesium; Mortality; Population attributable fraction

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; MAGNESIUM; PARATHYROID HORMONE; POTASSIUM; SERUM ALBUMIN;

ADULT; AGED; ARTICLE; ATRIAL FIBRILLATION; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; FEMALE; FOLLOW UP; HEMODIALYSIS PATIENT; HUMAN; JAPAN; MAGNESIUM BLOOD LEVEL; MAGNESIUM METABOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM;

EID: 84959327040     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sfv097     Document Type: Article

References (27)

1. Kanbay M, Goldsmith D, Uyar ME et al. Magnesium in chronic kidney disease: challenges and opportunities. Blood Purif 2010; 29: 280-292
2. Touyz RM. Role of magnesium in the pathogenesis of hypertension. Mol Aspects Med 2003; 24: 107-136
3. Carrero JJ, Aguilera A, Stenvinkel P et al. Appetite disorders in Uremia. J Ren Nutr 2008; 18: 107-113
4. Malpuech-Brugère C, Nowacki W, Daveau M et al. Inflammatory response following acute magnesium deficiency in the rat. Biochim Biophys Acta 2000; 1501: 91-98
5. Ishimura E, Okuno S, Kitatani K et al. Significant association between the presence of peripheral vascular calcification and lower serum magnesium in hemodialysis patients. Clin Nephrol 2007; 68: 222-227
6. Liao F, Folsom AR, Brancati FL. Is low magnesium concentration a risk factor for coronary heart disease? The Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 1998; 136: 480-490
7. Rude RK, Singer FR. Magnesium deficiency and excess. Annu Rev Med 1981; 32: 245-259
8. Ishimura E, Okuno S, Yamakawa T et al. Serum magnesium concentration is a significant predictor of mortality in maintenance hemodialysis patients. Magnes Res 2007; 20: 237-244
9. Sakaguchi Y, Fujii N, Shoji T et al. Hypomagnesemia is a significant predictor of cardiovascular and non-cardiovascular mortality in patients undergoing hemodialysis. Kidney Int 2014; 85: 174-181
10. Fukuhara S, Akizawa T, Fukagawa M et al. Mineral and bone disorders outcomes study for Japanese chronic kidney disease stage 5D patients: rationale and study design. Ther Apher Dial 2011; 15: 169-175
11. Dekker FW, de Mutsert R, van Dijk PC et al. Survival analysis: time-dependent effects and time-varying risk factors. Kidney Int 2008; 74: 994-997
12. Jankowska EA, Rozentryt P, Ponikowska B et al. Circulating es-tradiol and mortality in men with systolic chronic heart failure. JAMA 2009; 301: 1892-1901
13. Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Apher Dial 2008; 12: 514-525
14. SAS Institute, Inc. SAS/STAT® User's Guide, Version 8. Cary, NC; SAS Institute, Inc., 1999, 1452
15. Klein J, Moeschberger M. Survival Analysis Techniques for Censored and Truncated Data. New York; Springer, 1997, 416-418
16. Kurita N, Yamazaki S, Fukumori N et al. Overactive bladder symptom severity is associated with falls in community-dwelling adults: LOHAS study. BMJ Open 2013;3:e002413, http://dx.doi.org/10.1136/bmjopen-2012-002413
17. Greenland S, Drescher K. Maximum likelihood estimation of the attributable fraction from logistic models. Biometrics 1993; 49: 865-872
18. Roger N. PUNAFCC: Stata module to compute population attributable fractions for case-control and survival studies. http://ideas.repec.org/c/boc/bocode/s457354.html
19. Harrell FE. Hmisc: Harrell Miscellaneous. http://www.cran. r-project.org/web/packages/Hmisc/index.html
20. The Japanese Society for Dialysis Therapy. An overview of regular dialysis treatment in Japan (As of December 31, 2012). http://docs.jsdt.or.jp/overview/pdf2013/p040.pdf
21. Khan AM, Lubitz SA, Sullivan LM et al. Low serum magnesium and the development of atrial fibrillation in the community: the Framingham Heart Study. Circulation 2013; 127: 33-38
22. de Baaij JHF, Hoenderop JGJ, Bindels RJM. Regulation of magnesium balance: lessons learned from human genetic disease. Clin Kidney J 2012; 5 (Suppl 1): i15-i24
23. João Matias P, Azevedo A, Laranjinha I et al. Lower serum magnesium is associated with cardiovascular risk factors and mortality in haemodialysis patients. Blood Purif 2015; 38: 244-252
24. Pletka P, Bernstein DS, Hampers CL et al. Relationship between magnesium and secondary hyperparathyroidism during long-term hemodialysis. Metabolism 1974; 23: 619-630
25. Tzanakis I, Virvidakis K, Tsomi A et al. Intra-and extracellular magnesium levels and atheromatosis in haemodialysis patients. Magnesium Res 2004; 17: 102-108
26. Kovesdy CP, Regidor DL, Mehrotra R et al. Serum and dialysate potassium concentrations and survival in hemodialysis patients. Clin J Am Soc Nephrol 2007; 2: 999-1007
27. Sumukadas D, McMurdo MET, Habicht D. Proton pump inhibitors are associated with lower magnesium levels in older people with chronic kidney disease. J Am Geriatr Soc 2012; 60: 392-393